Daniel LaBarbera
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
DNA-Binding Proteins | 6 | 2023 | 1384 | 2.170 |
Why?
| Spheroids, Cellular | 4 | 2020 | 57 | 1.770 |
Why?
| Antineoplastic Agents | 11 | 2022 | 1990 | 1.710 |
Why?
| DNA Helicases | 3 | 2023 | 136 | 1.670 |
Why?
| Drug Discovery | 7 | 2022 | 128 | 1.490 |
Why?
| Aldehyde Reductase | 7 | 2018 | 101 | 1.490 |
Why?
| Epithelial-Mesenchymal Transition | 5 | 2021 | 182 | 1.440 |
Why?
| Neoplasms | 5 | 2023 | 2235 | 1.420 |
Why?
| Drug Screening Assays, Antitumor | 8 | 2020 | 190 | 1.400 |
Why?
| DNA Topoisomerases, Type II | 5 | 2019 | 45 | 1.290 |
Why?
| Topoisomerase II Inhibitors | 3 | 2019 | 23 | 1.290 |
Why?
| Acridines | 3 | 2014 | 7 | 1.250 |
Why?
| Enzyme Inhibitors | 5 | 2020 | 836 | 1.170 |
Why?
| Cell Line, Tumor | 19 | 2022 | 2904 | 1.080 |
Why?
| Hydrolyzable Tannins | 4 | 2014 | 10 | 1.060 |
Why?
| Urinary Bladder Neoplasms | 3 | 2022 | 211 | 1.060 |
Why?
| Antigens, Neoplasm | 3 | 2016 | 228 | 0.980 |
Why?
| TCF Transcription Factors | 2 | 2020 | 21 | 0.920 |
Why?
| Plant Extracts | 2 | 2017 | 169 | 0.910 |
Why?
| Colorectal Neoplasms | 2 | 2020 | 646 | 0.900 |
Why?
| High-Throughput Screening Assays | 5 | 2020 | 126 | 0.880 |
Why?
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 76 | 0.880 |
Why?
| Small Molecule Libraries | 4 | 2020 | 83 | 0.810 |
Why?
| Cell Plasticity | 1 | 2021 | 25 | 0.780 |
Why?
| Imidazoles | 5 | 2021 | 234 | 0.760 |
Why?
| Clonal Evolution | 1 | 2020 | 26 | 0.730 |
Why?
| Neoplasm Proteins | 2 | 2020 | 415 | 0.700 |
Why?
| Cell Culture Techniques | 2 | 2020 | 354 | 0.700 |
Why?
| Histones | 1 | 2023 | 562 | 0.660 |
Why?
| Naegleria fowleri | 1 | 2017 | 1 | 0.630 |
Why?
| Larrea | 1 | 2017 | 1 | 0.630 |
Why?
| Entamoeba histolytica | 1 | 2017 | 7 | 0.630 |
Why?
| Antiprotozoal Agents | 1 | 2017 | 12 | 0.620 |
Why?
| Giardia lamblia | 1 | 2017 | 17 | 0.620 |
Why?
| Drug Design | 5 | 2022 | 163 | 0.610 |
Why?
| Neoplastic Stem Cells | 4 | 2020 | 340 | 0.590 |
Why?
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 24 | 0.560 |
Why?
| Imaging, Three-Dimensional | 2 | 2017 | 511 | 0.530 |
Why?
| Adenosine Triphosphate | 3 | 2019 | 456 | 0.520 |
Why?
| Hepatocytes | 1 | 2015 | 206 | 0.500 |
Why?
| Colonic Neoplasms | 2 | 2016 | 230 | 0.500 |
Why?
| Porifera | 3 | 2009 | 8 | 0.500 |
Why?
| beta Catenin | 1 | 2016 | 223 | 0.480 |
Why?
| Amidines | 1 | 2013 | 16 | 0.480 |
Why?
| Heterocyclic Compounds | 1 | 2013 | 21 | 0.480 |
Why?
| Glycosides | 1 | 2013 | 34 | 0.470 |
Why?
| Breast Neoplasms | 4 | 2017 | 1994 | 0.470 |
Why?
| Adenocarcinoma | 1 | 2020 | 837 | 0.460 |
Why?
| Amides | 1 | 2013 | 88 | 0.460 |
Why?
| Phyllanthus emblica | 1 | 2012 | 4 | 0.430 |
Why?
| Retinoids | 1 | 2012 | 35 | 0.430 |
Why?
| Apoptosis | 7 | 2021 | 2532 | 0.410 |
Why?
| Image Processing, Computer-Assisted | 1 | 2015 | 739 | 0.400 |
Why?
| Fruit | 1 | 2012 | 134 | 0.390 |
Why?
| Cell Survival | 5 | 2021 | 1075 | 0.390 |
Why?
| Humans | 38 | 2023 | 122796 | 0.380 |
Why?
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 99 | 0.380 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1183 | 0.380 |
Why?
| Promoter Regions, Genetic | 7 | 2022 | 1188 | 0.370 |
Why?
| Transcription, Genetic | 3 | 2021 | 1355 | 0.360 |
Why?
| Keratin-5 | 3 | 2017 | 47 | 0.360 |
Why?
| Telomerase | 2 | 2022 | 213 | 0.360 |
Why?
| Alkaloids | 1 | 2009 | 23 | 0.360 |
Why?
| Mice | 14 | 2023 | 15888 | 0.350 |
Why?
| Drug Resistance, Neoplasm | 2 | 2021 | 673 | 0.350 |
Why?
| Quinoxalines | 2 | 2007 | 62 | 0.320 |
Why?
| Thyroid Carcinoma, Anaplastic | 2 | 2019 | 37 | 0.320 |
Why?
| Catalytic Domain | 2 | 2023 | 210 | 0.320 |
Why?
| Caspases | 1 | 2009 | 275 | 0.320 |
Why?
| Models, Molecular | 6 | 2015 | 1443 | 0.320 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 204 | 0.320 |
Why?
| Models, Biological | 3 | 2017 | 1756 | 0.310 |
Why?
| Cell Proliferation | 7 | 2021 | 2328 | 0.300 |
Why?
| Molecular Structure | 6 | 2016 | 463 | 0.300 |
Why?
| Thyroid Neoplasms | 2 | 2021 | 277 | 0.290 |
Why?
| Animals | 18 | 2023 | 34133 | 0.290 |
Why?
| Antibiotics, Antineoplastic | 2 | 2006 | 115 | 0.280 |
Why?
| Receptors, Progesterone | 3 | 2017 | 326 | 0.250 |
Why?
| Structure-Activity Relationship | 4 | 2019 | 536 | 0.250 |
Why?
| Oncogenes | 2 | 2022 | 118 | 0.240 |
Why?
| Biomarkers, Tumor | 2 | 2022 | 1076 | 0.240 |
Why?
| Poly ADP Ribosylation | 1 | 2023 | 8 | 0.240 |
Why?
| Benzimidazoles | 1 | 2005 | 142 | 0.240 |
Why?
| Indoles | 1 | 2006 | 318 | 0.240 |
Why?
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 40 | 0.230 |
Why?
| Progesterone | 3 | 2017 | 243 | 0.230 |
Why?
| Integrins | 1 | 2022 | 83 | 0.210 |
Why?
| Tripartite Motif-Containing Protein 28 | 1 | 2021 | 7 | 0.210 |
Why?
| Neoplasm Metastasis | 2 | 2016 | 563 | 0.200 |
Why?
| HEK293 Cells | 3 | 2012 | 651 | 0.190 |
Why?
| DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 14 | 0.190 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 159 | 0.190 |
Why?
| Carcinogenesis | 1 | 2022 | 184 | 0.190 |
Why?
| RNA, Neoplasm | 1 | 2020 | 79 | 0.190 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 179 | 0.180 |
Why?
| Mutation | 5 | 2022 | 3493 | 0.180 |
Why?
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 27 | 0.180 |
Why?
| Induced Pluripotent Stem Cells | 1 | 2022 | 188 | 0.180 |
Why?
| Glioblastoma | 1 | 2022 | 262 | 0.180 |
Why?
| Binding, Competitive | 1 | 2019 | 205 | 0.180 |
Why?
| Organoids | 1 | 2020 | 81 | 0.180 |
Why?
| HIV Protease | 1 | 2019 | 3 | 0.170 |
Why?
| Gene Knockdown Techniques | 1 | 2020 | 322 | 0.170 |
Why?
| Cell Cycle | 2 | 2014 | 584 | 0.170 |
Why?
| PTEN Phosphohydrolase | 1 | 2020 | 149 | 0.170 |
Why?
| Depsipeptides | 2 | 2011 | 15 | 0.170 |
Why?
| Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.170 |
Why?
| Nuclear Proteins | 1 | 2023 | 618 | 0.170 |
Why?
| Vascular Remodeling | 1 | 2020 | 158 | 0.170 |
Why?
| Wnt Signaling Pathway | 1 | 2020 | 153 | 0.170 |
Why?
| HIV Protease Inhibitors | 1 | 2019 | 65 | 0.170 |
Why?
| Drug Resistance | 1 | 2019 | 169 | 0.160 |
Why?
| alpha-Glucosidases | 1 | 2018 | 10 | 0.160 |
Why?
| Solanum tuberosum | 1 | 2018 | 9 | 0.160 |
Why?
| alpha-Amylases | 1 | 2018 | 17 | 0.160 |
Why?
| Polyphenols | 1 | 2018 | 20 | 0.160 |
Why?
| Masoprocol | 1 | 2017 | 3 | 0.160 |
Why?
| Naphthols | 1 | 2017 | 7 | 0.160 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 243 | 0.160 |
Why?
| DNA Damage | 1 | 2020 | 368 | 0.160 |
Why?
| Retinoic Acid Receptor alpha | 1 | 2017 | 11 | 0.160 |
Why?
| Viral Nonstructural Proteins | 1 | 2018 | 60 | 0.160 |
Why?
| Kaplan-Meier Estimate | 1 | 2020 | 884 | 0.150 |
Why?
| Receptors, Retinoic Acid | 1 | 2017 | 42 | 0.150 |
Why?
| Chikungunya virus | 1 | 2018 | 64 | 0.150 |
Why?
| Mice, Nude | 3 | 2021 | 668 | 0.150 |
Why?
| Oncogene Proteins, Fusion | 1 | 2019 | 182 | 0.150 |
Why?
| Down Syndrome | 1 | 2022 | 371 | 0.150 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 361 | 0.150 |
Why?
| Transcriptome | 1 | 2022 | 774 | 0.150 |
Why?
| Recombinant Proteins | 1 | 2020 | 1318 | 0.140 |
Why?
| Emodin | 1 | 2016 | 4 | 0.140 |
Why?
| Biological Products | 2 | 2011 | 166 | 0.140 |
Why?
| Receptors, Estrogen | 3 | 2017 | 388 | 0.140 |
Why?
| Xanthines | 1 | 2015 | 15 | 0.140 |
Why?
| Protein Interaction Maps | 1 | 2016 | 36 | 0.140 |
Why?
| Marine Toxins | 1 | 2015 | 13 | 0.140 |
Why?
| Dose-Response Relationship, Drug | 2 | 2011 | 1981 | 0.140 |
Why?
| Tretinoin | 2 | 2017 | 119 | 0.140 |
Why?
| Sorbitol | 2 | 2012 | 26 | 0.140 |
Why?
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.140 |
Why?
| Virus Replication | 1 | 2018 | 409 | 0.130 |
Why?
| Microglia | 2 | 2014 | 214 | 0.130 |
Why?
| Protein-Tyrosine Kinases | 1 | 2019 | 442 | 0.130 |
Why?
| Progestins | 2 | 2012 | 78 | 0.130 |
Why?
| Retinal Pigments | 1 | 2014 | 6 | 0.130 |
Why?
| Acid Phosphatase | 1 | 2014 | 18 | 0.130 |
Why?
| Rhodamines | 1 | 2014 | 19 | 0.130 |
Why?
| G2 Phase | 1 | 2014 | 35 | 0.130 |
Why?
| Lens, Crystalline | 2 | 2016 | 126 | 0.130 |
Why?
| Neoplasm Transplantation | 2 | 2019 | 248 | 0.130 |
Why?
| Neoplasm Invasiveness | 1 | 2016 | 472 | 0.120 |
Why?
| Diabetes Mellitus, Experimental | 1 | 2016 | 213 | 0.120 |
Why?
| Diabetes Complications | 1 | 2016 | 226 | 0.120 |
Why?
| Quinones | 1 | 2013 | 12 | 0.120 |
Why?
| Drug Stability | 1 | 2013 | 157 | 0.120 |
Why?
| Retinal Diseases | 1 | 2014 | 81 | 0.120 |
Why?
| Cataract | 1 | 2016 | 194 | 0.120 |
Why?
| Transcription Factors | 1 | 2021 | 1616 | 0.110 |
Why?
| Endotoxins | 1 | 2014 | 234 | 0.110 |
Why?
| Green Fluorescent Proteins | 2 | 2012 | 402 | 0.110 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1402 | 0.110 |
Why?
| Miconazole | 1 | 2012 | 4 | 0.110 |
Why?
| Acitretin | 1 | 2012 | 4 | 0.110 |
Why?
| Genetic Variation | 1 | 2018 | 952 | 0.110 |
Why?
| Isotretinoin | 1 | 2012 | 23 | 0.110 |
Why?
| Hydrobromic Acid | 1 | 2012 | 2 | 0.110 |
Why?
| RNA, Messenger | 1 | 2020 | 2720 | 0.110 |
Why?
| Antiviral Agents | 1 | 2018 | 670 | 0.110 |
Why?
| Hyaluronan Receptors | 1 | 2012 | 96 | 0.110 |
Why?
| Luciferases | 1 | 2012 | 150 | 0.110 |
Why?
| Tissue Culture Techniques | 1 | 2012 | 69 | 0.110 |
Why?
| Eye | 1 | 2012 | 108 | 0.100 |
Why?
| Inhibitory Concentration 50 | 1 | 2011 | 82 | 0.100 |
Why?
| Drug Evaluation, Preclinical | 1 | 2012 | 187 | 0.100 |
Why?
| Retina | 1 | 2014 | 277 | 0.100 |
Why?
| Genes, Reporter | 1 | 2012 | 274 | 0.100 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2012 | 143 | 0.100 |
Why?
| Oxazoles | 1 | 2011 | 31 | 0.100 |
Why?
| Software | 1 | 2015 | 631 | 0.100 |
Why?
| Hyperglycemia | 1 | 2014 | 326 | 0.100 |
Why?
| Vimentin | 1 | 2011 | 62 | 0.100 |
Why?
| Tumor Cells, Cultured | 1 | 2012 | 904 | 0.090 |
Why?
| Female | 8 | 2021 | 63629 | 0.090 |
Why?
| In Vitro Techniques | 1 | 2011 | 1130 | 0.090 |
Why?
| Inflammation Mediators | 1 | 2012 | 515 | 0.090 |
Why?
| Macrophages | 2 | 2014 | 1334 | 0.090 |
Why?
| Lipopolysaccharides | 1 | 2012 | 875 | 0.090 |
Why?
| Oxidation-Reduction | 1 | 2012 | 931 | 0.080 |
Why?
| Neoplasms, Experimental | 1 | 2009 | 162 | 0.080 |
Why?
| Epithelial Cells | 1 | 2014 | 995 | 0.080 |
Why?
| Cells, Cultured | 4 | 2022 | 4162 | 0.080 |
Why?
| Heat-Shock Response | 1 | 2008 | 60 | 0.080 |
Why?
| Stereoisomerism | 1 | 2007 | 94 | 0.080 |
Why?
| Hydrocarbons, Halogenated | 1 | 2007 | 5 | 0.080 |
Why?
| Computer Simulation | 1 | 2012 | 945 | 0.080 |
Why?
| Quinolines | 1 | 2008 | 127 | 0.080 |
Why?
| Mycotoxins | 1 | 2006 | 3 | 0.070 |
Why?
| Beauveria | 1 | 2006 | 2 | 0.070 |
Why?
| Pyrroles | 1 | 2007 | 199 | 0.070 |
Why?
| Angiogenesis Inhibitors | 1 | 2008 | 223 | 0.070 |
Why?
| Protein Binding | 1 | 2012 | 2010 | 0.070 |
Why?
| Mice, Inbred C57BL | 3 | 2020 | 5020 | 0.070 |
Why?
| Quinolones | 1 | 2007 | 97 | 0.070 |
Why?
| Fungal Proteins | 1 | 2006 | 132 | 0.070 |
Why?
| Solutions | 1 | 2006 | 154 | 0.070 |
Why?
| Catalysis | 1 | 2006 | 295 | 0.070 |
Why?
| Peptides, Cyclic | 1 | 2007 | 260 | 0.070 |
Why?
| Imidazolidines | 2 | 2014 | 19 | 0.060 |
Why?
| Hydrogen-Ion Concentration | 1 | 2006 | 547 | 0.060 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 839 | 0.060 |
Why?
| Melanoma, Experimental | 1 | 2005 | 116 | 0.060 |
Why?
| Models, Chemical | 1 | 2005 | 273 | 0.060 |
Why?
| Oxidative Stress | 2 | 2022 | 1204 | 0.060 |
Why?
| Proto-Oncogene Proteins c-ret | 1 | 2022 | 25 | 0.060 |
Why?
| Kinetics | 1 | 2006 | 1658 | 0.050 |
Why?
| Inflammation | 1 | 2012 | 2598 | 0.050 |
Why?
| Oximes | 1 | 2021 | 18 | 0.050 |
Why?
| Reactive Oxygen Species | 2 | 2014 | 592 | 0.050 |
Why?
| Indazoles | 1 | 2021 | 61 | 0.050 |
Why?
| Mass Spectrometry | 2 | 2018 | 686 | 0.050 |
Why?
| Platelet-Derived Growth Factor | 1 | 2020 | 85 | 0.050 |
Why?
| Drug Synergism | 1 | 2021 | 346 | 0.050 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 294 | 0.050 |
Why?
| Azacitidine | 1 | 2020 | 119 | 0.040 |
Why?
| MAP Kinase Signaling System | 1 | 2021 | 304 | 0.040 |
Why?
| Depsides | 1 | 2018 | 1 | 0.040 |
Why?
| Piperazines | 1 | 2021 | 326 | 0.040 |
Why?
| Proteolysis | 1 | 2019 | 149 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 747 | 0.040 |
Why?
| Myocytes, Smooth Muscle | 1 | 2020 | 244 | 0.040 |
Why?
| Vero Cells | 1 | 2018 | 69 | 0.040 |
Why?
| DNA Mismatch Repair | 1 | 2018 | 29 | 0.040 |
Why?
| Salicylates | 1 | 2018 | 32 | 0.040 |
Why?
| RNA Caps | 1 | 2018 | 35 | 0.040 |
Why?
| Pharmacogenomic Variants | 1 | 2018 | 35 | 0.040 |
Why?
| Cell Line | 2 | 2018 | 2785 | 0.040 |
Why?
| Cricetinae | 1 | 2018 | 269 | 0.040 |
Why?
| Lactones | 1 | 2018 | 57 | 0.040 |
Why?
| Anthocyanins | 1 | 2018 | 30 | 0.040 |
Why?
| Fluorescence | 1 | 2018 | 164 | 0.040 |
Why?
| Neoplasm Grading | 1 | 2018 | 265 | 0.040 |
Why?
| Stem Cells | 1 | 2021 | 576 | 0.040 |
Why?
| Gene Frequency | 1 | 2018 | 522 | 0.040 |
Why?
| Aldo-Keto Reductases | 1 | 2016 | 10 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2019 | 421 | 0.040 |
Why?
| Colchicine | 1 | 2015 | 27 | 0.030 |
Why?
| Tubulin Modulators | 1 | 2015 | 11 | 0.030 |
Why?
| Chromatography, Liquid | 1 | 2018 | 356 | 0.030 |
Why?
| Tumor Suppressor Proteins | 1 | 2018 | 299 | 0.030 |
Why?
| Molecular Docking Simulation | 1 | 2015 | 102 | 0.030 |
Why?
| Genetic Testing | 1 | 2018 | 400 | 0.030 |
Why?
| Treatment Outcome | 1 | 2009 | 9692 | 0.030 |
Why?
| Protein Kinase Inhibitors | 1 | 2021 | 833 | 0.030 |
Why?
| Tubulin | 1 | 2015 | 126 | 0.030 |
Why?
| Membrane Potential, Mitochondrial | 1 | 2014 | 59 | 0.030 |
Why?
| Cell Differentiation | 1 | 2022 | 1805 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2018 | 1234 | 0.030 |
Why?
| Computational Biology | 1 | 2018 | 601 | 0.030 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2014 | 131 | 0.030 |
Why?
| MAP Kinase Kinase 4 | 1 | 2012 | 25 | 0.030 |
Why?
| Extracellular Matrix | 1 | 2017 | 461 | 0.030 |
Why?
| Diabetic Retinopathy | 1 | 2014 | 156 | 0.030 |
Why?
| MCF-7 Cells | 1 | 2012 | 115 | 0.030 |
Why?
| Uveitis | 1 | 2012 | 116 | 0.030 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 290 | 0.030 |
Why?
| Blotting, Western | 1 | 2014 | 1225 | 0.020 |
Why?
| Mice, Inbred BALB C | 1 | 2014 | 1245 | 0.020 |
Why?
| Analysis of Variance | 1 | 2014 | 1329 | 0.020 |
Why?
| Mice, Transgenic | 1 | 2016 | 2079 | 0.020 |
Why?
| Algorithms | 1 | 2018 | 1593 | 0.020 |
Why?
| Prognosis | 1 | 2018 | 3563 | 0.020 |
Why?
| Cell Movement | 1 | 2014 | 929 | 0.020 |
Why?
| Glucose | 1 | 2014 | 968 | 0.020 |
Why?
| Flow Cytometry | 1 | 2012 | 1128 | 0.020 |
Why?
| Marine Biology | 1 | 2007 | 3 | 0.020 |
Why?
| HSP90 Heat-Shock Proteins | 1 | 2008 | 46 | 0.020 |
Why?
| Toxicity Tests, Acute | 1 | 2007 | 11 | 0.020 |
Why?
| Fiji | 1 | 2007 | 3 | 0.020 |
Why?
| Antibiotics, Antitubercular | 1 | 2006 | 35 | 0.020 |
Why?
| Spectrum Analysis | 1 | 2006 | 89 | 0.020 |
Why?
| Cytokines | 1 | 2014 | 1928 | 0.020 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2008 | 513 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 241 | 0.020 |
Why?
| Binding Sites | 1 | 2008 | 1247 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2014 | 3799 | 0.020 |
Why?
| Signal Transduction | 1 | 2017 | 4902 | 0.010 |
Why?
| Mycobacterium tuberculosis | 1 | 2006 | 304 | 0.010 |
Why?
| Amino Acids | 1 | 2006 | 463 | 0.010 |
Why?
| Aged | 1 | 2019 | 20495 | 0.010 |
Why?
| Middle Aged | 1 | 2019 | 28563 | 0.010 |
Why?
| Male | 1 | 2012 | 59639 | 0.000 |
Why?
|
|
LaBarbera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|